DIM — Sartorius Stedim Biotech SA Share Price
- €17.50bn
- €19.98bn
- €2.78bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 42.62 | ||
PEG Ratio (f) | 2.29 | ||
EPS Growth (f) | 22.91% | ||
Dividend Yield (f) | 0.43% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.5 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 57.37 | ||
Price to Sales | 6.37 | ||
EV to EBITDA | 29.38 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.51% | ||
Return on Equity | 5.24% | ||
Operating Margin | 14.43% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 1,440.57 | 1,910.08 | 2,886.98 | 3,492.7 | 2,775.5 | 2,763.37 | 3,001.22 | 18.02% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +30.62 | +38.7 | +19.85 | +111.49 | -56.33 | -21.96 | +26.77 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Directors
- Joachim Kreuzburg CHM (56)
- Chrystel Baudere NED
- Rene Faber NED (45)
- Lothar Kappich NED (64)
- Henri Riey NED (59)
- Pascale Boissel NID (54)
- Susan Dexter NID (65)
- Anne-Marie Graffin NID (60)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 1st, 1978
- Public Since
- October 20th, 1994
- No. of Employees
- 10,382
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 97,315,214
- Address
- Bp 1051, Aubagne Cedex, AUBAGNE, 13781
- Web
- https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
- Phone
- +33 442845600
- Contact
- Petra Kirchhoff
- Auditors
- Deloitte & Associes
Upcoming Events for DIM
Q4 2024 Sartorius AG Earnings Release
Similar to DIM
AbL Diagnostics SA
Euronext - Paris
Affluent Medical SAS
Euronext - Paris
Alpha MOS SA
Euronext - Paris
Amplitude Surgical SA
Euronext - Paris
Aton SA
Euronext - Paris
FAQ
As of Today at 22:05 UTC, shares in Sartorius Stedim Biotech SA are trading at €179.80. This share price information is delayed by 15 minutes.
Shares in Sartorius Stedim Biotech SA last closed at €179.80 and the price had moved by -11.47% over the past 365 days. In terms of relative price strength the Sartorius Stedim Biotech SA share price has underperformed the FTSE Global All Cap Index by -20.05% over the past year.
The overall consensus recommendation for Sartorius Stedim Biotech SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Sartorius Stedim Biotech SA dividend yield is 0.38% based on the trailing twelve month period.
Last year, Sartorius Stedim Biotech SA paid a total dividend of €0.69, and it currently has a trailing dividend yield of 0.38%. We do not have any data on when Sartorius Stedim Biotech SA is to next pay dividends.
We do not have data on when Sartorius Stedim Biotech SA is to next pay dividends. The historic dividend yield on Sartorius Stedim Biotech SA shares is currently 0.38%.
To buy shares in Sartorius Stedim Biotech SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €179.80, shares in Sartorius Stedim Biotech SA had a market capitalisation of €17.50bn.
Here are the trading details for Sartorius Stedim Biotech SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: DIM
Based on an overall assessment of its quality, value and momentum Sartorius Stedim Biotech SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sartorius Stedim Biotech SA is €218.20. That is 21.36% above the last closing price of €179.80.
Analysts covering Sartorius Stedim Biotech SA currently have a consensus Earnings Per Share (EPS) forecast of €3.37 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sartorius Stedim Biotech SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -2.41%.
As of the last closing price of €179.80, shares in Sartorius Stedim Biotech SA were trading -7.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sartorius Stedim Biotech SA PE ratio based on its reported earnings over the past 12 months is 42.62. The shares last closed at €179.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sartorius Stedim Biotech SA's management team is headed by:
- Joachim Kreuzburg - CHM
- Chrystel Baudere - NED
- Rene Faber - NED
- Lothar Kappich - NED
- Henri Riey - NED
- Pascale Boissel - NID
- Susan Dexter - NID
- Anne-Marie Graffin - NID